Source: Lieyun Network
Recently, TowardPi (Beijing) Medical Technology Co., Ltd. (hereinafter referred to as "TowardPi") completed its shareholding system reform and a nearly 400-million-yuan Pre-IPO round of financing within the month. This round of financing was led by Chengdu Science and Technology Investment Group, with participation from Beijing Pharmaceutical and Health Industry Fund and Sichuan Science and Technology Investment Group. Existing shareholders Matrix Partners, Beijing Robotics Industry Development Investment Fund, Tsinghua Holdings Jinxin Capital, Chang Development Group, Qing Shi Asset Management Group, Daoyuan Capital, and Haoyue Capital continued to increase their investments.
It is reported that the funds raised this time will effectively strengthen the company's cash reserve during the preparation process for going public, providing strong financial support for subsequent IPO efforts, deepening global layout, and improving the full-category product matrix.
Including this round, TowardPi has completed three rounds of equity financing within a year, with a cumulative total reaching 1 billion yuan, attracting numerous globally renowned investment institutions. These include the Social Security Fund Zhongguancun Independent Innovation Special Fund (managed by Legend Capital), Beijing Medical and Health Industry Fund, Beijing Robotics Industry Development Investment Fund (jointly managed by ShouCheng Holdings and JingGuoRui), Matrix Partners China, Qiming Venture Partners, and Beijing State-owned Capital Operation and Management Center.
Tianyancha shows that TowardPi was established in 2017. Its core technology originates from the transformation of scientific and technological achievements at Tsinghua University and was incubated by the Tsinghua Industrial Innovation Research Institute. The core technical team of TowardPi consists of dozens of teachers and students from various specialties such as electronics, biomedical engineering, and precision instruments at Tsinghua University. Relying on Tsinghua's technological platform, they have developed a series of globally leading high-end medical devices. The company currently has a staff of over 300 people, including more than 100 in the R&D team, with an annual R&D investment of nearly 100 million RMB. TowardPi has R&D centers in Beijing and Shanghai, as well as manufacturing bases in Beijing, Suzhou, and Tianjin.
It is reported that TowardPi's product lines cover ophthalmic OCT, surgical microscopes, ultra-wide-field fundus cameras, optical biometers, etc. Its products are sold in dozens of countries worldwide, with ophthalmic femtosecond laser and phaco-vitrectomy product lines currently under development.
Chengdu Science and Technology Investment Group stated: Since its establishment, TowardPi has addressed the challenge of integrating medical and engineering expertise and responded with an integrated approach to industry and research. In the journey toward the indigenization of high-end ophthalmic equipment, it has written an innovative chapter from 0 to 1 and from 1 to N, serving as a typical example of local medical device companies breaking through "bottleneck" technologies and achieving import substitution. We firmly believe in TowardPi's strategic path of "high-end positioning and full-spectrum layout," and we look forward to its growth into a world-class brand representing China's high-end manufacturing going global, armed with cutting-edge product strength and systematic services, competing head-to-head with international giants in the global ophthalmic medical equipment arena.